Several brokerages have updated their recommendations and price targets on shares of Phathom Pharmaceuticals (NASDAQ: PHAT) in the last few weeks:
- 10/30/2026 – Phathom Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright.
- 10/30/2026 – Phathom Pharmaceuticals had its “buy” rating reaffirmed by Citigroup.
- 10/21/2026 – Phathom Pharmaceuticals had its “buy” rating reaffirmed by Craig Hallum. They now have a $15.00 price target on the stock.
- 10/15/2026 – Phathom Pharmaceuticals had its “sell (d-)” rating reaffirmed by Weiss Ratings.
- 10/14/2026 – Phathom Pharmaceuticals had its “buy” rating reaffirmed by Jefferies Financial Group. They now have a $16.00 price target on the stock.
- 9/9/2026 – Phathom Pharmaceuticals is now covered by Leerink Partners. They set a “market perform” rating and a $10.00 price target on the stock.
- 9/9/2026 – Phathom Pharmaceuticals is now covered by Leerink Partners. They set a “hold” rating and a $10.00 price target on the stock.
Phathom Pharmaceuticals Stock Down 4.8%
PHAT traded down $0.28 during midday trading on Tuesday, hitting $5.62. 796,768 shares of the company were exchanged, compared to its average volume of 1,293,471. The firm has a market capitalization of $455.06 million, a P/E ratio of -5.46 and a beta of 0.50. Phathom Pharmaceuticals, Inc. has a 1-year low of $5.01 and a 1-year high of $18.31. The firm’s 50 day moving average price is $7.58 and its 200-day moving average price is $10.42.
Phathom Pharmaceuticals, Inc (NASDAQ: PHAT) is a biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal diseases. The company’s principal product is Voquezna (vonoprazan), a potassium-competitive acid blocker designed to suppress stomach acid through a mechanism distinct from traditional proton pump inhibitors.
In the United States, Voquezna is approved for the treatment of Helicobacter pylori infection in combination with antibiotics and for certain forms of gastroesophageal reflux disease (GERD), including erosive esophagitis and heartburn associated with non-erosive GERD.
Read More
- Five stocks we like better than Phathom Pharmaceuticals
- Republic Services Has the Momentum, But Waste Management Has Another Advantage
- Alphabet’s Golden Dome Talks Could Open a New Market, But How Much Is at Stake?
- Tempus AI Surges on Earnings Beat, But Can the Rally Last?
- MicroVision Pivots: Mapping New Ground Beyond Auto
Receive News & Ratings for Phathom Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phathom Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.
